Access
To read this article in full you may need to log in, make a payment or gain access through a site license (see right).
Perspective
Nature Reviews Cancer 4, 988–993 (1 December 2004) | doi:10.1038/nrc1507
CpG island methylator phenotype in cancer
Abstract
DNA hypermethylation in CpG-rich promoters is now recognized as a common feature of human neoplasia. However, the pathophysiology of hyper-methylation (why, when, where) remains obscure. Cancers can be classified according to their degree of methylation, and those cancers with high degrees of methylation (the CpG island methylator phenotype, or CIMP) represent a clinically and aetiologically distinct group that is characterized by 'epigenetic instability'. Furthermore, CIMP-associated cancers seem to have a distinct epidemiology, a distinct histology, distinct precursor lesions and distinct molecular features.
To read this article in full you may need to log in, make a payment or gain access through a site license (see right).
